JAK Inhibitor Risk Assessment Tool
Your Risk Assessment
This tool helps you understand your personalized risk of serious infections and blood clots when taking JAK inhibitors based on key factors identified in clinical studies.
Risk Assessment Results
Based on your responses
Key Recommendations
When you're living with rheumatoid arthritis, psoriatic arthritis, or another autoimmune condition, finding a treatment that actually works can feel like a breakthrough. JAK inhibitors - drugs like tofacitinib, baricitinib, and upadacitinib - have become popular because they often work when other medications fail. But behind the promise of relief lies a real and growing concern: JAK inhibitors can increase your risk of serious infections and blood clots. This isn’t theoretical. It’s backed by years of clinical data, regulatory warnings, and real patient stories.
How JAK Inhibitors Work - And Why They Raise Red Flags
JAK inhibitors block specific enzymes inside immune cells called Janus kinases. These enzymes help trigger inflammation, which is why these drugs are so effective at calming down autoimmune flare-ups. But inflammation isn’t just a problem - it’s also your body’s defense system. When you shut down parts of that system, you leave yourself vulnerable.
Think of it like turning off the alarm system in your house. The burglar (inflammation) stays out - great. But now, so does the firefighter (your immune response). That’s why patients on JAK inhibitors see more cases of pneumonia, urinary tract infections, and, most notably, shingles. In fact, herpes zoster (shingles) shows up in over 14% of infection reports linked to these drugs. Even if you’ve been vaccinated, the protection isn’t foolproof. One patient on Reddit described being hospitalized for five days after developing shingles just three months after starting tofacitinib - despite having received the vaccine.
The Blood Clot Risk: More Than Just a Statistic
The biggest safety shock came in 2021, when the FDA added a black box warning - its strongest possible alert - for JAK inhibitors. The warning covered three major risks: serious infections, cancer, major heart events, and blood clots. The trigger? A four-year study called ORAL Surveillance that followed over 4,300 patients with rheumatoid arthritis.
The numbers were stark. Patients on tofacitinib had a 73% higher risk of pulmonary embolism (a clot in the lungs) and a 33% higher risk of dying from any cause compared to those on TNF inhibitors. Deep vein thrombosis (DVT) - clots forming in the legs - rose by 2.29 times. And it’s not just tofacitinib. All JAK inhibitors carry this risk, though some appear riskier than others.
Why does this happen? It’s not just one mechanism. JAK2 inhibition affects platelet production and blood flow regulation. Studies show JAK inhibitors can reduce thrombopoietin signaling - a key hormone that helps make platelets. At the same time, inflammation itself promotes clotting, and suppressing it too much might destabilize the body’s natural balance. The result? A perfect storm for clots, especially in people who already have risk factors.
Who’s at Highest Risk?
Not everyone on a JAK inhibitor will get a blood clot. But certain people are far more vulnerable:
- Patients over 65
- Those with a prior history of blood clots (DVT or pulmonary embolism)
- People who smoke - current or former
- Individuals with obesity (BMI ≥30)
- Anyone on estrogen therapy (like hormone replacement or birth control pills)
- Those who’ve been immobile for long periods (e.g., after surgery or a long flight)
One study found that patients with a history of clots had over five times the risk of another event on JAK inhibitors. Another showed that people over 65 had nearly four times the risk compared to younger patients. That’s not a small increase - it’s a red flag.
Take the case of a 68-year-old man in Bristol who developed a deep vein thrombosis in his calf six months after starting upadacitinib. He’d just returned from a 10-hour flight. His rheumatologist immediately stopped the drug. He’s now on a different treatment - and he’s alive.
How Do the Different JAK Inhibitors Compare?
Not all JAK inhibitors are the same. Their chemical structure affects how tightly they bind to different JAK enzymes - and that changes the risk profile.
| Drug (Brand) | JAK Target | Dosing | Thrombosis Risk | Infection Risk |
|---|---|---|---|---|
| Tofacitinib (Xeljanz) | JAK1/JAK3 > JAK2 | 5 mg twice daily (RA) 10 mg twice daily (UC) |
High - strongest signal in ORAL Surveillance | High - most common infection: shingles |
| Baricitinib (Olumiant) | JAK1/JAK2 | 2-4 mg once daily | High - similar to tofacitinib | High - especially respiratory infections |
| Upadacitinib (Rinvoq) | JAK1-selective | 15 mg once daily | Lower than tofacitinib (but still present) | High - shingles and pneumonia common |
| Filgotinib (Jyseleca) | JAK1-selective (minimal JAK2) | 200 mg once daily | Potentially lower - data still limited | High - similar to others |
Upadacitinib, for example, appears to have a lower clotting signal than tofacitinib - especially in patients without other risk factors. The JAKARTA2 trial in 2023 showed just 0.2 clot events per 100 patient-years with upadacitinib, compared to 0.9 with tofacitinib. That’s promising, but not a guarantee. All JAK inhibitors carry a warning. The FDA and EMA both state the risk applies across the entire class.
What You Need to Do Before Starting
If your doctor is considering a JAK inhibitor, don’t just say yes. Ask these questions:
- Have I had a blood clot before? (Even one years ago counts.)
- Do I smoke - or have I ever smoked?
- Is my BMI over 30?
- Am I on estrogen therapy?
- Have I been immobile for long periods recently?
- Have I had shingles before? (Vaccination doesn’t guarantee full protection.)
Before starting, you should get:
- Updated vaccines - especially herpes zoster (Shingrix), pneumococcal, and flu shots. Live vaccines (like the old shingles vaccine) are strictly forbidden while on these drugs.
- A baseline blood test - including D-dimer (a clot marker) and a lower extremity ultrasound if you’re high-risk.
- A lipid panel - JAK inhibitors raise cholesterol. Total cholesterol can jump 15-20% within four weeks. That’s not harmless - it adds to your cardiovascular risk.
Monitoring doesn’t stop after the first dose. Blood counts, liver enzymes, and lipids need checking every 4-8 weeks. The American College of Rheumatology recommends this. Many practices now use digital checklists to ensure nothing gets missed.
What Happens If You Get a Blood Clot or Infection?
If you develop signs of a clot - sudden leg swelling, pain, shortness of breath, chest pain - go to the ER. Don’t wait. Your doctor will stop the JAK inhibitor immediately. You’ll likely need blood thinners for at least three months.
If you get a serious infection - fever over 38°C for more than 24 hours, cough that won’t quit, urinary pain, or skin sores - call your rheumatologist. You’ll need antibiotics or antivirals, and the drug will be paused until you’re fully recovered.
One patient on Drugs.com wrote: "I got pneumonia on upadacitinib. Took me three weeks to feel normal again. My doctor said never to go back on it." That’s not rare. Nearly 42% of negative reviews cite infections as the reason they stopped treatment.
Is It Still Worth It?
Some patients say these drugs changed their lives. One woman in Manchester stopped using a walker after six months on baricitinib. Another with severe alopecia areata regained all her hair. For many, the benefits outweigh the risks - if they’re carefully managed.
But here’s the truth: JAK inhibitors are not first-line anymore. They’re second- or third-line. The European League Against Rheumatism and the American College of Rheumatology both recommend trying TNF inhibitors or other biologics first. JAK inhibitors are powerful, but they’re not safer. They’re just different.
The market has shifted. In 2020, JAK inhibitors made up 35% of new prescriptions for rheumatoid arthritis. By 2023, that dropped to 28%. TNF inhibitors are back on top. Why? Because doctors are getting smarter about risk.
What’s Next?
Newer drugs are coming. TYK2 inhibitors - a more targeted version of JAK blockers - are in late-stage trials. Early data suggests they may work just as well with fewer side effects. But they’re not here yet.
Right now, the message is clear: JAK inhibitors work. But they come with real, measurable dangers. If you’re considering one, don’t just trust your doctor’s word. Ask for the data. Review your personal risk factors. Understand what you’re signing up for.
This isn’t about fear. It’s about informed choice. You deserve relief - but not at the cost of your life.
Emma Deasy
March 15, 2026 AT 18:51Let me just say this: JAK inhibitors are not just drugs-they’re a gamble with your life. I’ve seen three patients in my clinic alone develop pulmonary embolisms within six months of starting tofacitinib. One was a 59-year-old woman who had never smoked, never had a clot-until she did. And now? She’s on lifelong anticoagulants. The FDA warning? It’s not a suggestion. It’s a siren. And yet, so many rheumatologists still push these as ‘first-line alternatives.’ That’s not medical practice-it’s negligence. I’ve filed complaints. I’ve written to the AMA. No one listens. But someone has to speak up.